EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

EyePoint (Nasdaq: EYPT) announced that George O. Elston, EVP and CFO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 AM ET.

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) announced that George O. Elston, EVP and CFO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 AM ET. A live webcast and archived replay will be available via the company Investors website at www.eyepoint.bio.

Argus Feb 5 session

+3.24% close to close Open Argus

Details

News Market Reaction – EYPT

On Feb 5, the day this news came out, EYPT closed 3.24% above the previous close.

Data tracked by StockTitan Argus for the Feb 5 session.

Market Context

This announcement highlights continued investor outreach through participation in the Guggenheim Eme...

Analysis

This announcement highlights continued investor outreach through participation in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. It follows recent updates on DURAVYU Phase 3 progress, corporate milestones, and routine equity grants. Together, these communications underscore a focus on visibility ahead of planned 2026 catalysts. Investors may watch future disclosures on pivotal trial readouts, cash runway, and any additional corporate developments to assess how the story evolves.

Key Figures

Summit date: February 12, 2026 Event time: 11:00 am ET

Summit date

February 12, 2026

Scheduled Guggenheim Emerging Outlook: Biotech Summit fireside chat

Event time

11:00 am ET

Scheduled start of EyePoint fireside chat

Historical Context

5 past events · Latest: Jan 16

5 events

1. Jan 16

   Inducement option grants

   24h Move

   -4.8%

   New employee inducement stock options granted under Nasdaq Listing Rule 5635(c)(4).

2. Jan 07

   Corporate milestones update

   24h Move

   +3.0%

   Outlined 2026 DURAVYU milestones, Phase 3 enrollment status, and cash runway.

3. Dec 17

   Conference presentation

   24h Move

   -1.6%

   Announced CEO presentation and webcast at J.P. Morgan Healthcare Conference.

4. Dec 16

   Inducement option grants

   24h Move

   +3.2%

   Granted stock options to new employees with four-year vesting terms.

5. Nov 19

   Phase 3 DSMC update

   24h Move

   +2.3%

   DSMC found no safety signals and recommended Phase 3 trials continue unchanged.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 am ET.

A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will EyePoint (EYPT) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

EyePoint will present on Thursday, February 12, 2026 at 11:00 AM ET. According to EyePoint, George O. Elston, EVP and CFO, will take part in a fireside chat discussing company developments and strategy during the summit session.

Who from EyePoint (EYPT) is speaking at the Guggenheim Biotech Summit 2026?

George O. Elston, Executive Vice President and Chief Financial Officer, will participate in the fireside chat. According to EyePoint, Elston will represent the company and discuss financial and strategic topics relevant to investors at the event.

How can investors watch EyePoint's (EYPT) Guggenheim Summit presentation and replay?

Investors can access a live webcast and archived replay via the company's Investors webpage at www.eyepoint.bio. According to EyePoint, the webcast will be available at the scheduled time with a subsequent archived replay for later viewing on the investor site.

What topics will EyePoint (EYPT) likely cover in the fireside chat at the biotech summit?

The fireside chat will focus on company developments, financial outlook, and strategy for retinal therapeutics. According to EyePoint, the session aims to update investors on progress in development and commercialization efforts for its retinal-disease portfolio.